Estimating the proportion of young adults on antihypertensive treatment that have been correctly diagnosed

Marshall, Tom; Tennant, Ruth; Harrison, Wayne

doi:10.1038/sj.jhh.1002291

Cited by 3 publications

(2 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This is an important finding as these patients would have been labelled as poorly controlled hypertensive patients when they were not. Similar findings were seen previously [9].…”

Section: Not All Patients Were Poorly Controlledsupporting

confidence: 92%

Experience from a pilot study of a nurse-led hypertension clinic in general practice

Ali

Walker

Crook

et al. 2010

Journal of Evaluation in Clinical Practice

View full text Add to dashboard Cite

“…This is an important finding as these patients would have been labelled as poorly controlled hypertensive patients when they were not. Similar findings were seen previously [9].…”

Section: Not All Patients Were Poorly Controlledsupporting

confidence: 92%

Experience from a pilot study of a nurse-led hypertension clinic in general practice

Ali

Walker

Crook

et al. 2010

Journal of Evaluation in Clinical Practice

View full text Add to dashboard Cite

“…This means assessment of all cardiovascular risk factors, using the mean of blood pressures taken at two clinic visits and a single measure of total cholesterol and HDL cholesterol. Variation in measured risk factors can have a significant impact on the identification of patients as eligible for treatment, it is therefore important to incorporate this effect into the model [ 7 - 10 ]. In order to model this, a "clinically determined" cardiovascular risk was calculated for each individual, based on the mean of two clinically measured blood pressures and cholesterol levels [ 1 ].…”

Section: Methodsmentioning

confidence: 99%

Identification of patients for clinical risk assessment by prediction of cardiovascular risk using default risk factor values

Marshall

2008

BMC Public Health

View full text Add to dashboard Cite

Background: To identify high risk patients without cardiovascular disease requires assessment of risk factors. Primary care providers must therefore determine which patients without cardiovascular disease should be highest priority for cardiovascular risk assessment. One approach is to prioritise patients for assessment using a prior estimate of their cardiovascular risk. This prior estimate of cardiovascular risk is derived from risk factor data that are routinely held in electronic medical records, with unknown blood pressure and cholesterol levels replaced by default values derived from national survey data. This paper analyses the test characteristics of using such a strategy for identification of high risk patients.

show abstract

Hypertension in practice: towards the year 2010

Beevers¹

2008

Therapy

View full text Add to dashboard Cite

Rapidly detectable and easily accessible markers of tumor cell death are needed for evaluating early therapeutic efficacy for immunotherapy and chemotherapy so that patients and their physicians can decide whether to remain with a given therapeutic strategy. Currently, image-based tests such as computed tomography scans and magnetic resonance imaging are used to visualize the response of a patient's tumor, but often these evaluations are not conducted for weeks to months after treatment begins. While serum levels of secreted proteins such as carcinoembryonic antigen and prostate specific antigen are commonly monitored to gauge tumor status during therapy and between image evaluations, the levels of these proteins do not always correlate well with the actual tumor response. In laboratory studies, it has been shown that tumor cells undergoing apoptosis can release cellular components into cell culture media such as cytochrome c, nucleosomes, cleaved cytokeratin-18 and E-cadherin. Studies of patient sera have found that these and other macromolecules can be found in circulation during cancer therapy, providing a potential source of material for monitoring treatment efficacy. In the future, analysis of biofluids from severe combined immunodeficiency mice bearing patient tumor specimens treated with a targeted therapy such as Apo2L/tumor necrosis factor-related apoptosis-inducing ligand will be useful in the preclinical identification of therapy response markers. In this review, the current status of the identification of serum markers of tumor cell apoptosis is provided, as well as a discussion of critical research questions that must be addressed and the considerations necessary when identifying a marker that reflects true clinical outcome.

show abstract

Estimating the proportion of young adults on antihypertensive treatment that have been correctly diagnosed

Cited by 3 publications

References 10 publications

Experience from a pilot study of a nurse-led hypertension clinic in general practice

Experience from a pilot study of a nurse-led hypertension clinic in general practice

Identification of patients for clinical risk assessment by prediction of cardiovascular risk using default risk factor values

Hypertension in practice: towards the year 2010

Contact Info

Product

Resources

About